{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:34:45Z","timestamp":1788305685474,"version":"build-2803163510"},"reference-count":82,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institutes of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI088744"],"award-info":[{"award-number":["R01AI088744"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R43AI092924"],"award-info":[{"award-number":["R43AI092924"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Layer-by-layer microparticle (LbL-MP) fabrication was used to produce synthetic vaccines presenting a fusion peptide containing RSV G protein CX3C chemokine motif and a CD8 epitope of the RSV matrix protein 2 (GM2) with or without a covalently linked TLR2 agonist (Pam3.GM2). Immunization of BALB\/c mice with either GM2 or Pam3.GM2 LbL-MP in the absence of adjuvant elicited G-specific antibody responses and M2-specific CD8+ T-cell responses. Following challenge with RSV, mice immunized with the GM2 LbL-MP vaccine developed a Th2-biased immune response in the lungs with elevated levels of IL-4, IL-5, IL-13, and eotaxin in the bronchoalveolar lavage (BAL) fluid and a pulmonary influx of eosinophils. By comparison, mice immunized with the Pam3.GM2 LbL-MP vaccine had considerably lower to non-detectable levels of the Th2 cytokines and chemokines and very low numbers of eosinophils in the BAL fluid post-RSV challenge. In addition, mice immunized with the Pam3.GM2 LbL-MP also had higher levels of RSV G-specific IgG2a and IgG2b in the post-challenge BAL fluid compared to those immunized with the GM2 LbL-MP vaccine. While both candidates protected mice from infection following challenge, as evidenced by the reduction or elimination of RSV plaques, the inclusion of the TLR2 agonist yielded a more potent antibody response, greater protection, and a clear shift away from Th2\/eosinophil responses. Since the failure of formalin-inactivated RSV (FI-RSV) vaccines tested in the 1960s has been hypothesized to be partly due to the ablation of host TLR engagement by the vaccine and inappropriate Th2 responses upon subsequent viral infection, these findings stress the importance of appropriate engagement of the innate immune response during initial exposure to RSV G CX3C.<\/jats:p>","DOI":"10.3390\/vaccines10122078","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T07:07:31Z","timestamp":1670224051000},"page":"2078","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge"],"prefix":"10.3390","volume":"10","author":[{"given":"Thomas J.","family":"Powell","sequence":"first","affiliation":[{"name":"Artificial Cell Technologies, 5 Science Park, Suite 13, New Haven, CT 06511, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Artificial Cell Technologies, 5 Science Park, Suite 13, New Haven, CT 06511, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tang","sequence":"additional","affiliation":[{"name":"Artificial Cell Technologies, 5 Science Park, Suite 13, New Haven, CT 06511, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Cardenas","sequence":"additional","affiliation":[{"name":"Artificial Cell Technologies, 5 Science Park, Suite 13, New Haven, CT 06511, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Palath","sequence":"additional","affiliation":[{"name":"Artificial Cell Technologies, 5 Science Park, Suite 13, New Haven, CT 06511, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Daniels","sequence":"additional","affiliation":[{"name":"Artificial Cell Technologies, 5 Science Park, Suite 13, New Haven, CT 06511, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Boyd","sequence":"additional","affiliation":[{"name":"Artificial Cell Technologies, 5 Science Park, Suite 13, New Haven, CT 06511, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1329-0209","authenticated-orcid":false,"given":"Harrison C.","family":"Bergeron","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Jorquera","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2924-9956","authenticated-orcid":false,"given":"Ralph A.","family":"Tripp","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/cid\/cis211","article-title":"Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993\u20132008","volume":"54","author":"Zhou","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1099\/0022-1317-78-10-2419","article-title":"Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants","volume":"78","author":"Martinez","year":"1997","journal-title":"J. Gen. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/infdis\/163.4.693","article-title":"Immunity to and frequency of reinfection with respiratory syncytial virus","volume":"163","author":"Hall","year":"1991","journal-title":"J. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1128\/JVI.78.7.3524-3532.2004","article-title":"The soluble form of human respiratory syncytial virus attachment protein differs from the membrane-bound form in its oligomeric state but is still capable of binding to cell surface proteoglycans","volume":"78","author":"Rawling","year":"2004","journal-title":"J. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1542\/peds.2013-2449","article-title":"RSV immunoprophylaxis: Does the benefit justify the cost?","volume":"132","author":"Meissner","year":"2013","journal-title":"Pediatrics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00431-021-04216-7","article-title":"Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab","volume":"181","author":"Sato","year":"2022","journal-title":"Eur. J. Pediatr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/oxfordjournals.aje.a120957","article-title":"Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population","volume":"89","author":"Chin","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/oxfordjournals.aje.a120956","article-title":"Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine","volume":"89","author":"Fulginiti","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/oxfordjournals.aje.a120954","article-title":"An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine","volume":"89","author":"Kapikian","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1128\/jcm.26.8.1595-1597.1988","article-title":"Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity","volume":"26","author":"Murphy","year":"1988","journal-title":"J. Clin. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nm.1894","article-title":"Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease","volume":"15","author":"Delgado","year":"2009","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12026-007-0071-6","article-title":"Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease","volume":"39","author":"Castilow","year":"2007","journal-title":"Immunol. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1128\/jvi.68.8.5321-5325.1994","article-title":"Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB\/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10","volume":"68","author":"Connors","year":"1994","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1128\/CVI.00316-10","article-title":"How innate immune mechanisms contribute to antibody-enhanced viral infections","volume":"17","author":"Ubol","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/80833","article-title":"Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus","volume":"1","author":"Popova","year":"2000","journal-title":"Nat. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1099\/0022-1317-73-9-2225","article-title":"Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus","volume":"73","author":"Arbiza","year":"1992","journal-title":"J. Gen. Virol"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.vaccine.2012.11.009","article-title":"Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine","volume":"31","author":"Glenn","year":"2013","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJMoa2106062","article-title":"Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy","volume":"386","author":"Simoes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wilmschen, S., Schneider, S., Peters, F., Bayer, L., Issmail, L., Banki, Z., Grunwald, T., von Laer, D., and Kimpel, J. (2019). RSV Vaccine Based on Rhabdoviral Vector Protects after Single Immunization. Vaccines, 7.","DOI":"10.3390\/vaccines7030059"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/21645515.2020.1829899","article-title":"A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults","volume":"17","author":"Aliprantis","year":"2021","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/90675","article-title":"CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein","volume":"2","author":"Tripp","year":"2001","journal-title":"Nat. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.4049\/jimmunol.176.3.1600","article-title":"Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses","volume":"176","author":"Harcourt","year":"2006","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9831","DOI":"10.1128\/JVI.77.18.9831-9844.2003","article-title":"Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P","volume":"77","author":"Haynes","year":"2003","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1086\/600108","article-title":"Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB\/c mice","volume":"200","author":"Haynes","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1099\/vir.0.009308-0","article-title":"Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab\u2032)2 components mediates reduced pulmonary inflammation in mice","volume":"90","author":"Miao","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Nguyen, T.N., Power, U.F., Robert, A., Haeuw, J.F., Helffer, K., Perez, A., Asin, M.A., Corvaia, N., and Libon, C. (2012). The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0034331"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lee, H.J., Lee, J.Y., Park, M.H., Kim, J.Y., and Chang, J. (2017). Monoclonal Antibody against G Glycoprotein Increases Respiratory Syncytial Virus Clearance In Vivo and Prevents Vaccine-Enhanced Diseases. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0169139"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Jorquera, P.A., Choi, Y., Oakley, K.E., Powell, T.J., Boyd, J.G., Palath, N., Haynes, L.M., Anderson, L.J., and Tripp, R.A. (2013). Nanoparticle Vaccines Encompassing the Respiratory Syncytial Virus (RSV) G Protein CX3C Chemokine Motif Induce Robust Immunity Protecting from Challenge and Disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0074905"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/vaccines3040829","article-title":"Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease","volume":"3","author":"Jorquera","year":"2015","journal-title":"Vaccines"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1128\/JVI.00671-08","article-title":"Respiratory syncytial virus activates innate immunity through Toll-like receptor 2","volume":"83","author":"Murawski","year":"2009","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.2174\/1381612827666210716160030","article-title":"Interaction of Ectodomain of Respiratory Syncytial Virus G Protein with TLR2\/TLR6 Heterodimer: An In vitro and In silico Approach to Decipher the Role of RSV G Protein in Pro-inflammatory Response against the Virus","volume":"27","author":"Alshaghdali","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.4049\/jimmunol.180.4.2376","article-title":"IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease","volume":"180","author":"Castilow","year":"2008","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1128\/CVI.00609-15","article-title":"Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease","volume":"23","author":"Acosta","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.4049\/jimmunol.151.4.2032","article-title":"Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus","volume":"151","author":"Graham","year":"1993","journal-title":"J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1016\/S0264-410X(03)00482-1","article-title":"Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus","volume":"21","author":"Hancock","year":"2003","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1016\/S0264-410X(01)00228-6","article-title":"CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV)","volume":"19","author":"Hancock","year":"2001","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1128\/JVI.00983-14","article-title":"Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB\/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine","volume":"88","author":"Uda","year":"2014","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.vaccine.2013.02.027","article-title":"Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses","volume":"31","author":"Powell","year":"2013","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e3204","DOI":"10.1002\/btpr.3204","article-title":"Evaluation of single-use tangential flow filtration technology for purification of activated polysaccharides used in conjugate vaccine manufacturing","volume":"37","author":"Motevalian","year":"2021","journal-title":"Biotechnol. Prog."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"30326","DOI":"10.1021\/acsami.1c05750","article-title":"Scalable Purification of Plasmid DNA Nanoparticles by Tangential Flow Filtration for Systemic Delivery","volume":"13","author":"Liu","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Murray, J., Bergeron, H.C., Jones, L.P., Reener, Z.B., Martin, D.E., Sancilio, F.D., and Tripp, R.A. (2022). Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication. Viruses, 14.","DOI":"10.21203\/rs.3.rs-1280404\/v1"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0264-410X(92)90397-3","article-title":"Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia\u2014RSV recombinants or RSV","volume":"10","author":"Connors","year":"1992","journal-title":"Vaccine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1128\/JVI.03630-14","article-title":"Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection","volume":"89","author":"Brand","year":"2015","journal-title":"J. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e02180-16","DOI":"10.1128\/JVI.02180-16","article-title":"Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant","volume":"91","author":"Cayatte","year":"2017","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3389\/fimmu.2019.00597","article-title":"Unveiling Integrated Functional Pathways Leading to Enhanced Respiratory Disease Associated with Inactivated Respiratory Syncytial Viral Vaccine","volume":"10","author":"Russell","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/infdis\/jiab612","article-title":"A Randomized Phase 1\/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine","volume":"225","author":"Walsh","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e01302-17","DOI":"10.1128\/JVI.01302-17","article-title":"Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem","volume":"92","author":"Tripp","year":"2018","journal-title":"J. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1099\/vir.0.000218","article-title":"CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells","volume":"96","author":"Chirkova","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9632","DOI":"10.1128\/JVI.00451-10","article-title":"Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB\/c mice","volume":"84","author":"Radu","year":"2010","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"10955","DOI":"10.1128\/JVI.01164-13","article-title":"A Respiratory Syncytial Virus (RSV) Anti-G Protein F(ab\u2019)2 Monoclonal Antibody Suppresses Mucous Production and Breathing Effort in RSV rA2-line19F-Infected BALB\/c Mice","volume":"87","author":"Gaston","year":"2013","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Cheon, I.S., Shim, B.S., Park, S.M., Choi, Y., Jang, J.E., Jung, D.I., Kim, J.O., Chang, J., Yun, C.H., and Song, M.K. (2014). Development of Safe and Effective RSV Vaccine by Modified CD4 Epitope in G Protein Core Fragment (Gcf). PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0094269"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41541-022-00487-9","article-title":"Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle","volume":"7","author":"Pavot","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Kim, A.R., Lee, D.H., Lee, S.H., Rubino, I., Choi, H.J., and Quan, F.S. (2018). Protection induced by virus-like particle vaccine containing tandem repeat gene of respiratory syncytial virus G protein. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191277"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3389\/fimmu.2018.00678","article-title":"The CD8 T Cell Response to Respiratory Virus Infections","volume":"9","author":"Schmidt","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"13016","DOI":"10.1128\/JVI.01770-12","article-title":"Vaccine-Elicited CD8+ T Cells Protect against Respiratory Syncytial Virus Strain A2-Line19F-Induced Pathogenesis in BALB\/c Mice","volume":"86","author":"Lee","year":"2012","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/mi.2017.46","article-title":"Airway T cells protect against RSV infection in the absence of antibody","volume":"11","author":"Kinnear","year":"2018","journal-title":"Mucosal Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1166\/jbn.2017.2341","article-title":"Cellular Immune Correlates Preventing Disease Against Respiratory Syncytial Virus by Vaccination with Virus-Like Nanoparticles Carrying Fusion Proteins","volume":"13","author":"Lee","year":"2017","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.1096158","article-title":"Regulation of phagosome maturation by signals from toll-like receptors","volume":"304","author":"Blander","year":"2004","journal-title":"Science"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/ni1006-1029","article-title":"On regulation of phagosome maturation and antigen presentation","volume":"7","author":"Blander","year":"2006","journal-title":"Nat. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/CVI.00590-15","article-title":"Mucosal IgG Levels Correlate Better with Respiratory Syncytial Virus Load and Inflammation than Plasma IgG Levels","volume":"23","author":"Vissers","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.4049\/jimmunol.1001148","article-title":"Computational and experimental analysis reveals a requirement for eosinophil-derived IL-13 for the development of allergic airway responses in C57BL\/6 mice","volume":"186","author":"Walsh","year":"2011","journal-title":"J. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1067\/mai.2001.118600","article-title":"IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism","volume":"108","author":"Pope","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Rijavec, M., Krumpestar, T., Skrgat, S., Kern, I., and Korosec, P. (2021). T2-high Asthma, Classified by Sputum mRNA Expression of IL4, IL5, and IL13, is Characterized by Eosinophilia and Severe Phenotype. Life, 11.","DOI":"10.3390\/life11020092"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1002\/eji.1830260837","article-title":"Human eotaxin represents a potent activator of the respiratory burst of human eosinophils","volume":"26","author":"Elsner","year":"1996","journal-title":"Eur J. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1128\/JVI.01536-14","article-title":"Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease","volume":"89","author":"Su","year":"2015","journal-title":"J. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1615\/CritRevImmunol.v22.i2.10","article-title":"Regulation of macrophage-derived chemokine (MDC, CCL22) production","volume":"22","author":"Yamashita","year":"2002","journal-title":"Crit. Rev. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1189\/jlb.0502243","article-title":"The role of CCL22 (MDC) for the recruitment of eosinophils during allergic pleurisy in mice","volume":"73","author":"Pinho","year":"2003","journal-title":"J. Leukoc. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.0906-6705.2004.00149.x","article-title":"Thymus- and activation-regulated chemokine (TARC\/CCL17) induces a Th2-dominated inflammatory reaction on intradermal injection in mice","volume":"13","author":"Vestergaard","year":"2004","journal-title":"Exp. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1074\/jbc.272.9.5846","article-title":"Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2","volume":"272","author":"Hieshima","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/mt.sj.6300129","article-title":"Effects of MIP-1 alpha, MIP-3 alpha, and MIP-3 beta on the induction of HIV Gag-specific immune response with DNA vaccines","volume":"15","author":"Song","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Shafique, M., Meijerhof, T., Wilschut, J., and de Haan, A. (2013). Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: Effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061287"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1016\/j.vaccine.2006.03.064","article-title":"The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease","volume":"24","author":"Boukhvalova","year":"2006","journal-title":"Vaccine"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1016\/j.vaccine.2007.01.037","article-title":"C57Bl\/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine","volume":"25","author":"Cyr","year":"2007","journal-title":"Vaccine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"11692","DOI":"10.1128\/JVI.02018-15","article-title":"Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells","volume":"89","author":"Kim","year":"2015","journal-title":"J. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1128\/JVI.79.4.2050-2057.2005","article-title":"Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection","volume":"79","author":"Matthews","year":"2005","journal-title":"J. Virol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3904\/kjim.2021.093","article-title":"Eosinophil-mediated lung inflammation associated with elevated natural killer T cell response in COVID-19 patients","volume":"37","author":"Kim","year":"2022","journal-title":"Korean J. Intern. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2007-01-071340","article-title":"Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus","volume":"110","author":"Phipps","year":"2007","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.4049\/jimmunol.181.10.6692","article-title":"Cutting edge: Eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease","volume":"181","author":"Castilow","year":"2008","journal-title":"J. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"983812","DOI":"10.3389\/fimmu.2022.983812","article-title":"Eosinophils in filarial infections: Inducers of protection or pathology?","volume":"13","author":"Ehrens","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/12\/2078\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:34:21Z","timestamp":1760146461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/12\/2078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":82,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["vaccines10122078"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10122078","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,5]]}}}